Two Swedish companies, Cobra Biologics and Alligator Bioscience--which both decided to go with names of dangerous animals--have extended their cancer drug pact to a new mAb.
Under the terms of the deal, financial details of which were not disclosed, the two will work together to deliver a second cell line to manufacture the immuno-oncology antibody ADC-1015.
This follows on from the success they had with ADC-1013, which began early-stage testing last year.
That study, led by Alligator Bioscience, looked at the safety, pharmacokinetics and pharmacodynamics of intratumorally administered ADC-1013 in 40 patients during the dose escalation and expansion phases at 5 centers in the U.K., Denmark and Sweden.
Alligator said it has requested further support from the team at Cobra to develop the cell line for production of new drug candidate ADC-1015--a bispecific immune activator developed to induce superior immune activation.
Biologics and pharmaceuticals CDMO Cobra is using their expression system maxXpress, along with a historically documented master cell bank and chemically defined media. The company said that this delivers a “time saving cell line development and clone selection process suitable for GMP manufacture.”
Peter Coleman, CEO of Cobra Biologics, said: “I am delighted that Cobra has the opportunity to continue working with Alligator on their promising clinical programs and would like to congratulate the team on their prestigious SwedenBIO Award.”
Per Norlén, CEO of Alligator Bioscience, added: “Alligator has a long-standing and successful collaboration with Cobra and has seen very good results using their maxXpress system. We are very happy to continue the collaboration with Cobra on our ADC-1015 drug development program.”
- here's the statement